Qualit-E-SpeakPharma-Insert
X

Find Clinical Drug Pipelines for Obstetrics/Gynecology (Womens Health)

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
Study Phase filter
    Country filter
      News Type filter
        Company filter
          Product Type filter
            refresh

            Product Type

            Development Status

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SJX-653

            Therapeutic Area: Obstetrics/Gynecology (Womens Health)

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 24, 2020

            Details:

            The Phase 2 clinical trial is a 12-week, multi-center, randomized, double-blind, placebo-controlled study designed to evaluate the efficacy of SJX-653 in reducing vasomotor symptoms.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Segesterone Acetate,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Womens Health)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: TherapeuticsMD

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Agreement February 13, 2020

            Details:

            The arrangement combines Afaxys' unique capabilities serving the United States public health contraception market with TherapeuticsMD’s commitment to supply ANNOVERA to the U.S public health system.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Relugolix

            Therapeutic Area: Obstetrics/Gynecology (Womens Health)

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable February 10, 2020

            Details:

            Primary efficacy endpoint met with 87.7% response rate at one year; women experienced, on average, an 89.9% reduction in menstrual blood loss

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Estradiol,Nomegestrol Acetate

            Therapeutic Area: Obstetrics/Gynecology (Womens Health)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Theramex

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Acquisition January 22, 2020

            Details:

            Theramex currently markets Zoely® in eleven European countries, and this transaction will bring the total number of more than 50 on a global basis. MSD retains rights in the United States and Canada.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Etonogestrel,Ethinyl Estradiol

            Therapeutic Area: Obstetrics/Gynecology (Womens Health)

            Highest Development Status: Approved Product Type: Small molecule

            Partner/Sponsor/Collaborator: Farmitalia

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 21, 2020

            Details:

            Under the terms of the agreement, Farmitalia will distribute Myring™ in Italy, which is the third largest worldwide vaginal contraceptive ring market in terms of sales value and volume, after the US & Germany.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Nolasiban

            Therapeutic Area: Obstetrics/Gynecology (Womens Health)

            Highest Development Status: Phase III Product Type: Small molecule

            Partner/Sponsor/Collaborator: Yuyuan BioScience Technology

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 13, 2020

            Details:

            This sublicense agreement aims to develop and commercialize nolasiban for improving clinical pregnancy and live birth rates in women undergoing embryo transfer following in-vitro fertilization (IVF).